Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Despite Pricing Pressure, Humira Performing Strongly Across Most Metrics, Abbvie Says

Executive Summary

Humira continues its strong growth pace through volume gains and market share across therapeutic categories, CEO Gonzalez says, while leukemia drug Imbruvica also had a solid third quarter.


Related Content

Stockwatch: Has Sentiment Left the Biopharma Sector?
Shire Exits Biosimilars, Streamlines Oncology Business
Amgen’s Biggest Seller Enbrel Hit By Pricing Pressures, Competition
Another Strong Quarter For AbbVie, But How Long Will Good Times Last?
Imbruvica Boosts CLL Lead With First-Line Claim


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts